Neutra Corp Targets Expanded Sponsor and CRO Relationships in Q3 & Q4 2026, Reaffirming Full Commitment to Life Sciences Growth
HOUSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Neutra Corp (OTC: NTRR), a company focused on health, wellness, and life sciences, today announced its forward-looking strategy for the third and fourth…
Read the full articleYou might also wanna read
South Korea’s AimedBio Invests in Inocras, Partners on WGS for Cancer Trials
The companies hope to find patients likely to respond to AimedBio’s antibody-drug conjugates.
FDA Explores Expediting Clinical Trials: Announces Ambitious New Drug Pilot Program
On June 24, 2026, the Food and Drug Administration (FDA) published a notice of availability in the Federal Register requesting information a
Neurocrine Biosciences Inc (NASDAQ:NBIX) Scores High in Affordable Growth Screen
The "Affordable Growth" strategy targets stocks with strong growth and reasonable valuations. Neurocrine Biosciences (NBIX) fits perfectly,
Why Neutrogena is betting on science over skincare hype
The new brand mission aims to encourage consumers to move beyond skincare trends and viral beauty content by focusing on dermatologist-backe
The biotech bi-weekly: a disease modeling research grant and an accelerator program for data-driven health start-ups
In this edition of the biotech bi-weekly: a new companion module makes direct RNA sequencing protocols more convenient, antibiotic design an
Life Sciences Market Trends Q2 2026
The life sciences market remains optimistic, supported by continued momentum in manufacturing, steady clinical trial activity and FDA approv
Comments
Sign in to join the conversation.
No comments yet. Be the first.